The most consequential number on BioPivot’s website may not be its advertised starting price. Its homepage says a new patient’s first review is free and promises “$0 if you’re not approved.” Its cancellation policy, however, says an applicant declined after clinical review receives a membership refund minus a $59 doctor consultation fee. For someone deciding whether to submit payment, that is a concrete difference—not merely fine print about a future renewal.
BioPivot, LLC presents itself as a technology platform connecting patients with independent clinical and pharmacy services for compounded semaglutide and tirzepatide, including programs called microdosing. This documentary review examines what its prices buy, when charges recur and what happens if treatment does not proceed. The sources were consulted October 19, 2026; that is not necessarily their update date. The published offering is detailed enough to compare program prices, but not to establish a fully reconciled payment agreement without further written clarification.
At a glance
- Published semaglutide prices
- Compounded semaglutide Starter is $185 monthly or $400 quarterly; Continuation is $218 or $490; Maintenance is $225 or $518.Sources: [8]
- Published tirzepatide prices
- Compounded tirzepatide Starter is $242 monthly or $590 quarterly; Continuation is $315 or $780; Maintenance is $350 or $900.Sources: [3]
- Microdosing prices
- Compounded semaglutide microdosing is $168 monthly or $370 quarterly; compounded tirzepatide microdosing is $220 monthly or $528 quarterly.Sources: [5]
- First-review discrepancy
- The homepage advertises a free first review and $0 if not approved; the refund policy retains $59 after a provider reviews and declines treatment.
- Recurring-payment deadline
- Terms authorize an immediate charge and subsequent charges every 30 days for recurring monthly orders, with auto-refill cancellation at least 48 hours before processing.Sources: [7]
Establish the first charge before comparing monthly prices
BioPivot’s homepage advertises plans “from $149/mo,” confirmed after provider review. The consulted material does not identify the product or conditions behind that minimum. Its treatment-specific price lists start elsewhere, including $168 monthly for compounded semaglutide microdosing and $185 for semaglutide Starter. Consequently, the homepage minimum is not a usable quote for either of those named programs. Ask for the exact program, initial charge and billing interval together rather than budgeting from the banner alone.
The treatment pages also advertise 20% off a first order with code BIOPIVOT20, with prescribing subject to a licensed provider’s clinical judgment. That is an introductory offer, not a documented recurring discount. The evidence does not establish precisely how the code interacts with each quarterly option or the consultation-fee policy. Our guide to understanding the first GLP-1 payment explains why an advertised monthly amount and the amount collected at enrollment need separate confirmation.
Most importantly, obtain an answer to the free-review discrepancy before authorizing payment. The homepage’s $0-if-not-approved promise and the policy’s $59 retention cannot both describe the same outcome without an additional explanation. Ask which rule applies to your enrollment and what amount would be returned if a clinician declines treatment. This review cannot determine which statement BioPivot would apply in an individual transaction.
The full published menu—not just the lowest tier
BioPivot separates its principal compounded medication offers into Starter, Continuation and Maintenance tiers. The table preserves the published monthly and quarterly amounts without converting them into estimated monthly equivalents. Those are alternative advertised billing options, not evidence that every patient must prepay quarterly. The consulted descriptions do not expressly establish the GLP-1 administration route, concentration, presentation or quantity supplied under each price, so those details belong in the written quote.
The tier names also do not establish when an individual would move between prices. Nothing in the supplied evidence makes Starter a permanent rate, specifies an automatic transition date or defines the medication quantity attached to Maintenance. Ask which tier the clinician expects to prescribe and what would trigger a different charge. A higher-tier price is a budget consideration, but the labels alone are not patient dosing instructions or proof of a required treatment sequence.
The microdosing page lists compounded semaglutide at $168 monthly or $370 quarterly and compounded tirzepatide at $220 monthly or $528 quarterly. These are distinct named offers, not interchangeable versions of the Starter tiers. Their lower published prices do not establish equivalent treatment, better tolerability or a suitable option for an individual. The evidence supplied here does not establish provider-specific outcomes for any BioPivot program, including microdosing.
| Program tier | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| Starter | $185 monthly or $400 quarterly | $242 monthly or $590 quarterly |
| Continuation | $218 monthly or $490 quarterly | $315 monthly or $780 quarterly |
| Maintenance | $225 monthly or $518 quarterly | $350 monthly or $900 quarterly |
| Microdosing | $168 monthly or $370 quarterly | $220 monthly or $528 quarterly |
Monthly prices meet a three-month membership
The cancellation policy describes a three-month telehealth membership covering medical review, provider support, messaging and treatment fulfillment if approved. Separately, the terms say a recurring monthly order authorizes an immediate charge and another charge every 30 days until cancellation. Neither statement fully explains how a monthly selection relates to that three-month membership. In particular, a membership period does not by itself establish a minimum payment commitment or the quantity of medication supplied.
Quarterly prices add another unresolved layer. The consulted pages do not clearly establish whether those amounts are collected entirely at enrollment, how subsequent quarterly charges work or how quarterly enrollment interacts with monthly auto-refill language. A monthly amount and a quarterly amount should therefore be treated as published alternatives whose collection terms still need confirmation—not combined into a mandatory prepayment arrangement. Request actual transaction dates, rather than relying on the word “monthly.”
For recurring monthly orders, BioPivot says it sends electronic notice five to seven days before a scheduled transaction and a receipt after a successful charge. Its terms allow auto-refill cancellation up to 48 hours before the applicable monthly processing date. The distinction between calendar months and 30-day intervals matters for budgeting; our explanation of GLP-1 billing cycles offers a framework. The documents do not establish a long-term price lock.
What the bundle includes—and what could remain outside it
BioPivot’s terms describe one bundled subscription price comprising the pharmacy’s prescription-drug fee, the medical group’s provider-service fee and BioPivot’s platform-access charge. Treatment pages describe compounded medication prepared by partner pharmacies and shipped on a structured cadence. They also advertise direct physician messaging through a secure patient portal and structured check-ins. These are meaningful stated inclusions, although the consulted descriptions do not specify the exact frequency of supplies, appointments or reviews.
Laboratory spending is less settled. The homepage advertises baseline bloodwork and ongoing monitoring when a licensed provider considers them clinically appropriate. It separately lists a Comprehensive Panel for $228.30, including a blood count, metabolic panel, A1c, thyroid measures and other markers. The evidence does not clarify whether that charge is included in any medication program or would be additional. A Tasso at-home capillary collection kit is labeled “Coming soon,” with no available price.
The sources do not establish additional shipping charges, administration-supply costs, mandatory testing expenses or charges for consultations outside the package. Nor do they document insurance acceptance, insurer billing, out-of-network reimbursement or HSA/FSA use. Missing documentation does not establish that those options are unavailable. Before paying, request an itemized explanation using the distinctions in what a GLP-1 program price includes, especially for any laboratory work the clinician may request.
Who provides the services behind the payment
BioPivot, LLC identifies itself as the website owner and a technology platform, not the entity practicing medicine, providing clinical care, preparing medication or dispensing prescriptions. The homepage names Elite Care Health for clinical care and Rx Ave Health for pharmacy and prescription fulfillment. It describes independent U.S. board-certified clinical providers and state-licensed compounding pharmacies. Those are website statements; the supplied evidence does not independently verify credentials, pharmacy licenses or the particular preparing pharmacy for an individual prescription.
The stated process begins with a brief online intake reviewed by the care team. A licensed medical provider may request more information, laboratory work or a consultation before deciding whether to prescribe. BioPivot says most applicants hear back within 48 hours, but that is an applicant-response claim, not a medication dispatch or arrival promise. Completing intake or selecting a paid program does not guarantee treatment. The BMI calculator is described as a starting point rather than an eligibility determination.
The terms require users to be at least 18, or the local age of majority if higher, and physically in the same state as their account’s shipping address during a provider consultation. Potential availability in all 50 states is conditioned on clinical appropriateness and applicable law, not confirmed treatment-by-treatment coverage. The treatment page also excludes patients with specified thyroid-cancer or MEN 2 histories and those pregnant or breastfeeding, and says a full medical history is reviewed.
Cancellation changes meaning as the order progresses
Before a provider reviews the intake and clinical evaluation begins, the policy allows a full refund of paid membership or intake fees. After review, an applicant found unsuitable is promised the membership payment back minus $59. Once a prescription has been issued but treatment has not shipped, the policy describes a partial membership refund minus the same consultation fee. It does not clearly establish every possible retained amount through an itemized calculation.
Timing becomes especially important once the pharmacy receives an order. BioPivot asks patients seeking pre-shipment cancellation to email immediately and says cancellation cannot be guaranteed after transmission to the pharmacy. After compounded medication ships, sales are final except for stated pharmacy-error or damaged/incorrect-delivery exceptions. Turning off future enrollment is therefore different from reversing a current medication transaction. Our guide to cancellation and refunds explains that distinction without assuming cancellation creates a refund entitlement.
The policy provides account, email and telephone cancellation routes, says requests are processed within one business day and preserves remaining membership benefits through the three-month period. That must be read alongside the terms’ at-least-48-hour auto-refill deadline; the supplied documents do not explain which provision controls a conflict. Approved refunds are processed in five to ten business days to the original payment method, with another three to five business days potentially needed for the bank to show the credit.
Pharmacy restrictions and delivery protections affect value
BioPivot’s cancellation policy says medications dispensed through its service are custom compounded by licensed 503A pharmacies. Its terms also make purchasing a prescription-containing service conditional on accepting dispensing through the platform’s pharmacies rather than choosing another pharmacy. That is a material purchasing restriction for someone hoping to compare local dispensing prices. Rx Ave Health is identified as the fulfillment contact, but the supplied evidence does not establish which specific pharmacy would prepare each patient’s medication.
Treatment pages advertise temperature-controlled, unmarked packaging delivered discreetly. The terms separately warn that prescription products will not be dispensed in child-resistant containers. No preparation, dispatch or arrival schedule, carrier or exact supply cadence is established in the consulted material. For an injectable GLP-1 delivery that arrives warm or inadequately refrigerated, FDA explicitly advises not using the product and contacting the provider or dispensing pharmacy; a temperature-controlled-shipping claim does not replace that instruction.
For damaged orders or the wrong medication or dosage, BioPivot requires contact within seven days of delivery with photographs of the product and packaging, and promises to coordinate a no-cost replacement. For a shipment confirmed lost by tracking, the policy requires contact within 14 days of the expected delivery date and promises reshipment without an additional charge. These are defined problem-resolution pathways, not a general promise of refunds for every delivery delay or concern.
Put support access and product status into the cost decision
BioPivot lists general support at info@biopivot.co and 520-210-4673, with clinical hours Monday through Friday, 9 a.m. to 5 p.m.; the displayed block does not specify a time zone. Its contact form promises a team response within 24 hours, distinct from the homepage’s usual 48-hour applicant-response claim. Elite Care Health is listed at mayur@elite-care.health and 810-348-3003; Rx Ave Health at info@rxave.health and (833) 360-4276. These separate contacts help identify whom to approach about different parts of the bundle.
BioPivot acknowledges that compounded medications are not FDA approved. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence, but neither the published price nor the microdosing label establishes effectiveness or safety. FDA also reports measuring and administration errors involving compounded medication; instructions should be clarified with the prescriber or pharmacist, not inferred from program names.
Two documentary inconsistencies merit clarification alongside billing. The terms name Pura Labs LLC in a HIPAA clause without explaining its relationship to BioPivot. Separately, a general statement that BioPivot does not sell, rent or trade personal information appears alongside a California notice explaining that some advertising disclosures may count as a sale or sharing under that law. These passages do not support a legal verdict, but they make clear entity identification and readable enrollment disclosures more important.
Questions & answers
Can I enroll in a named BioPivot GLP-1 plan for $149?
The homepage advertises plans from $149 monthly, confirmed after provider review, but the consulted evidence does not identify the product or conditions attached to that minimum. The named compounded GLP-1 menus publish different amounts. Ask BioPivot to identify the exact $149 offering and provide its total first charge before treating the banner as your price.
Will I owe $59 if BioPivot’s clinician declines treatment?
The cancellation policy says yes: it describes refunding the membership payment minus a $59 doctor consultation fee after a provider determines the applicant is not a candidate. The homepage instead advertises $0 if not approved and a free first review. The evidence does not reconcile those statements. Obtain written confirmation of the applicable charge before submitting payment.
Does the quarterly price require three months paid upfront?
That collection requirement is not established in the supplied material. BioPivot publishes quarterly alternatives, describes a three-month membership and separately sets out immediate and every-30-day charges for recurring monthly orders. Ask whether your selected option is collected upfront, what renews and whether any remaining payment obligation survives cancellation. The three-month label alone does not answer those questions.
Are laboratory tests included in BioPivot’s medication price?
The evidence does not clearly establish that. BioPivot advertises laboratory monitoring when clinically appropriate and separately publishes a $228.30 Comprehensive Panel. Its terms bundle medication, medical-group services and platform access, but do not resolve whether that panel is included for your program. Ask what tests may be required, who bills them and what you would owe separately.
Can I have BioPivot’s prescription filled at my preferred pharmacy?
The terms condition purchase of a prescription-containing service on waiving pharmacy choice and using the platform’s pharmacy arrangement. Someone unwilling to accept that restriction is told not to purchase the service. The homepage names Rx Ave Health for fulfillment, but the supplied documents do not identify the particular preparing pharmacy that would handle every prescription.
How do I stop BioPivot’s next charge?
The terms say to turn off auto-refill in the portal at least 48 hours before the monthly processing date. The cancellation policy also offers Account > Subscription > Cancel Membership, email and telephone requests, processed within one business day. Request confirmation covering both membership and auto-refill. Stopping renewal does not establish a refund for an order already prescribed, transmitted or shipped.
Our assessment
BioPivot provides useful pricing detail across two compounded medications, multiple tiers and microdosing options, plus a stated bundle of medication, clinical services and platform access. Its named care and fulfillment contacts and specific delivery-remedy deadlines also help prospective patients prepare. The central cost weakness is reconciliation: the free-review promise conflicts with a $59 retention, while monthly, every-30-day, quarterly and three-month-membership language does not form one clear payment schedule. A sensible decision point is a written, program-specific quote confirming the first charge, renewal amount, commitment, laboratory costs and refund rules. Without that clarification, the published menu supports price comparison better than it supports predicting the full enrollment transaction.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.